Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
暂无分享,去创建一个
Sang-Heon Cho | S. Choe | Hyeong-Seok Lim | Seok-Joon Jin | H. Choi | K. Bae | J. Jung | J. Ghim | Hee-sun Kim
[1] G. Lippi,et al. Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.
[2] Yusong Chen,et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? , 2015, European Journal of Clinical Pharmacology.
[3] Yusong Chen,et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States , 2015, European Journal of Clinical Pharmacology.
[4] L Gong,et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update , 2014, Clinical pharmacology and therapeutics.
[5] L. Aarons,et al. Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach , 2014, Clinical pharmacology and therapeutics.
[6] M. Cosentino,et al. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2 , 2014, European Journal of Clinical Pharmacology.
[7] Sang-Heon Cho,et al. Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics , 2014, Pharmaceutical Research.
[8] M. Pirmohamed,et al. SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink , 2013, Clinical pharmacology and therapeutics.
[9] R. Hegele,et al. Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care , 2013, Circulation. Cardiovascular genetics.
[10] S. Zeng,et al. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. , 2013, Die Pharmazie.
[11] S. Kaul,et al. Evidence-based use of statins for primary prevention of cardiovascular disease. , 2012, The American journal of medicine.
[12] B. Tomlinson,et al. Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects , 2012, European Journal of Clinical Pharmacology.
[13] Wei Zhang,et al. Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs , 2011, Drug Metabolism and Disposition.
[14] M. Hayden,et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin , 2011, The Pharmacogenomics Journal.
[15] N. Samani,et al. Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.
[16] B. Tomlinson,et al. ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin , 2010, Clinical pharmacology and therapeutics.
[17] Yiannis S. Chatzizisis,et al. Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy , 2010, Drug safety.
[18] P. Neuvonen,et al. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. , 2009, Pharmacogenomics.
[19] G. Ginsburg,et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.
[20] J. Mega,et al. Identification of Genetic Variants Associated With Response to Statin Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[21] P. Neuvonen,et al. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.
[22] S. Bates,et al. ABCG2: a perspective. , 2009, Advanced drug delivery reviews.
[23] P. Neuvonen,et al. ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin , 2008, Clinical pharmacology and therapeutics.
[24] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[25] K. Maeda,et al. SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.
[26] L. Tremaine,et al. P-glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in mdr1a/b Knockout and Wild-Type Mice , 2007, Drug Metabolism and Disposition.
[27] T. Frudakis,et al. CYP2D6*4 polymorphism is associated with statin-induced muscle effects , 2007, Pharmacogenetics and genomics.
[28] C. Sirtori,et al. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. , 2007, Pharmacological research.
[29] Mikko Niemi,et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.
[30] Ya-li Liu,et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[31] M. Eichelbaum,et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events , 2006, Pharmacogenetics and genomics.
[32] M. Hutz,et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid‐lowering efficacy and safety of simvastatin treatment , 2005, Clinical pharmacology and therapeutics.
[33] Caroline A. Lee,et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.
[34] H. Masuya,et al. Statin response and pharmacokinetics variants , 2005, Expert opinion on pharmacotherapy.
[35] A. V. van Herwaarden,et al. Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver , 2005, Molecular Pharmacology.
[36] Julia Qiu,et al. Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin , 2004, Pharmaceutical Research.
[37] T. Strandberg,et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. , 2004, Pharmacogenetics.
[38] T. Sakaeda,et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[39] B. Ma,et al. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. , 2003, British journal of clinical pharmacology.
[40] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[41] B. Ma,et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[42] Bradford Ld. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .
[43] M. Haberl,et al. The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.
[44] I. Vermes,et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin , 2001, Clinical pharmacology and therapeutics.
[45] M. Mathai,et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. , 2001, Tennessee medicine : journal of the Tennessee Medical Association.
[46] Z. Ouyang,et al. Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. , 2000, Journal of pharmaceutical and biomedical analysis.
[47] M. Mercuri,et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. , 1999, The American journal of cardiology.
[48] R. Tyndale,et al. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. , 1998, Pharmacogenetics.
[49] B H Arison,et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[50] H. Lennernäs,et al. Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.
[51] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[52] V. F. Mauro. Clinical Pharmacokinetics and Practical Applications of Simvastatin , 1993, Clinical pharmacokinetics.
[53] Kazuya Maeda,et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.
[54] P. Neuvonen,et al. Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.
[55] Ulrich M. Zanger,et al. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[56] T. Leemann,et al. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.
[57] S. Grundy,et al. HMG-CoA reductase inhibitors for hypercholesterolemia. , 1988, The New England journal of medicine.